Reuters • 2 days ago
PARIS/DAVOS, Switzerland (Reuters) - For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker. Olivier Brandicourt's failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors. In an interview at the World Economic Forum in the Swiss resort of Davos this week Brandicourt defended his track record, citing an unwillingness to overpay for pricey assets and a paucity of good opportunities.
Zacks • 4 days ago
Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.
Reuters • 4 days ago
Two decades after they were spurred into action to tackle AIDS in Africa, global drugmakers said on Wednesday they would invest an initial $50 million over three years to fight cancer and other non-communicable diseases in poor countries. Twenty-two companies, including Pfizer, Merck , Novartis, Roche, Sanofi and GlaxoSmithKline, will contribute funds and expertise to the project, which is backed by the World Bank. The so-called Access Accelerated initiative was announced at the World Economic Forum in Davos and aims to improve both treatment and prevention.
Forbes • 6 days ago
Trump hasn’t yet entered the Oval Office, but he’s already showing an uncanny knack for creating quick stock dips with just a sentence or two.
Motley Fool • 7 days ago
Issues with programs developed in collaboration with Sanofi kept the otherwise promising biotech stock depressed.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||40.23 - 40.58|
|52 Week Range||36.81 - 44.50|
|PE Ratio (TTM)||23.45|
|Dividend & Yield||1.66 (4.12%)|
|1y Target Est||48.67|